Article
Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy.
European journal of cancer (Oxford, England : 1990) - 1 Jan 2006
Chan S K, Gullick W J, Hill M E
Abstract excerpt
The targeting of the ATP binding pocket of the epidermal growth factor receptor (EGFR) tyrosine kinase, by the small molecule drugs gefitinib and erlotinib, represents a promising new therapeutic strategy in non-small cell lung cancer. However, it is now apparent that only a subset of patients responds to such treatment. Two publications in early 2004 reported the presence of activating mutations in the EGFR...
Topics
- Carcinoma, Non-Small-Cell Lung
- Erlotinib Hydrochloride
- Female
- Gefitinib
- Genes, erbB-1
- Genetic Therapy
- Humans
- Lung Neoplasms
- Male
- Mutation
- Protein Kinase Inhibitors